Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial - Concepedia

Concepedia

Publication | Open Access

Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

DOI Full Paper Access

139

Citations

18

References

2022

Year

Qin Xu, Junjie Wang, Yang Sun, Yibin Lin, Jing Liu, Yanhong Zhuo, Zhangzhou Huang, Songhua Huang, Ying Chen, Li Chen,

Journal of Clinical Oncology

Abstract

Sintilimab plus anlotinib as second-line or later therapy is efficacious and safe for patients with advanced CA who have failed prior chemotherapy.

References

	Year	Citations

Page 1